Urinary orosomucoid: A new marker of cardiovascular risk in psoriatic patients?

Balázs Németh, Iván Péter, I. Boncz, Anna Jagicza, István Kiss, Ágnes Csergő, T. Kőszegi, Péter Kustán, I. Horváth, Zénó Ajtay

Research output: Contribution to journalArticle

Abstract

Purpose: Psoriasis is one of the most common lifelong lasting dermatologic diseases. According to the latest studies, psoriatic patients have a higher risk of developing cardiovascular diseases. Psoriasis is considered as a systemic inflammatory disease. Several oxidative stress markers have been shown to be elevated in psoriasis. However, a panel of biomarkers has not been used yet. This study was aimed at exploring the connection between a panel of biomarkers (C-reactive protein, asymmetric dimethylarginine, uric acid, total antioxidant capacity, malondialdehyde, and orosomucoid [ORM]) and cardiovascular risk in psoriatic patients. Patients and methods: The inclusion criterion was the onset of psoriasis with skin lesions. Exclusion criteria were impaired renal function (eGFR<60 mL/min/1.73 m2), acute inflammations (urinary, respiratory, skin inflammation, etc), autoimmune disorders (rheumatoid arthritis, systemic lupus erythematosus, or inflammatory bowel disease), and any kind of biological antipsoriatic treatment. Patients with a medical history of myocardial infarction, coronary heart disease, stroke, transient ischemic attack, and carotid artery stenosis were also excluded. Biomarkers were measured by routine procedures, ELISA and HPLC. QRISK®2-2017 was used to assess 10-year risk of cardiovascular disease development. Psoriasis severity was measured by the Psoriasis Area and Severity Index. Results: One hundred and fourteen psoriatic patients were enrolled. Only urinary orosomucoid and urinary orosomucoid/urinary creatinine (u-ORM/u-CREAT) ratio showed significant correlation with QRISK score (u-ORM, r=0.245; u-ORM/u-CREAT, r=0.309). When comparing mild psoriatic patients to moderate psoriatic patients, significant differences could only be found in u-ORM and u-ORM/u-CREAT ratio. Conclusion: There seems to be a connection between urinary ORM and cardiovascular risk. U-ORM and u-ORM/u-CREAT ratio could be used as an indicator of low-grade inflammation in mild and moderate psoriasis. However, it is the 10-year follow-up of cardiovascular events that will determine the usefulness of this biomarker panel.

Original languageEnglish
Pages (from-to)831-837
Number of pages7
JournalTherapeutics and Clinical Risk Management
Volume15
DOIs
Publication statusPublished - Jan 1 2019

Fingerprint

Orosomucoid
Biomarkers
Disease
Psoriasis
Skin
heart disease
stroke
Oxidative stress
Inflammation
Antioxidants
exclusion
inclusion
Cardiovascular Diseases
event
Proteins
Carotid Stenosis
Transient Ischemic Attack
Acids
Uric Acid
Malondialdehyde

Keywords

  • Biomarker
  • C-reactive protein
  • Cardiovascular risk
  • Orosomucoid
  • Oxidative stress
  • Psoriasis

ASJC Scopus subject areas

  • Safety Research
  • Pharmacology, Toxicology and Pharmaceutics(all)
  • Pharmacology (medical)
  • Chemical Health and Safety

Cite this

Urinary orosomucoid : A new marker of cardiovascular risk in psoriatic patients? / Németh, Balázs; Péter, Iván; Boncz, I.; Jagicza, Anna; Kiss, István; Csergő, Ágnes; Kőszegi, T.; Kustán, Péter; Horváth, I.; Ajtay, Zénó.

In: Therapeutics and Clinical Risk Management, Vol. 15, 01.01.2019, p. 831-837.

Research output: Contribution to journalArticle

Németh, Balázs ; Péter, Iván ; Boncz, I. ; Jagicza, Anna ; Kiss, István ; Csergő, Ágnes ; Kőszegi, T. ; Kustán, Péter ; Horváth, I. ; Ajtay, Zénó. / Urinary orosomucoid : A new marker of cardiovascular risk in psoriatic patients?. In: Therapeutics and Clinical Risk Management. 2019 ; Vol. 15. pp. 831-837.
@article{e9a810abf9c04f0db962a1595ad1de30,
title = "Urinary orosomucoid: A new marker of cardiovascular risk in psoriatic patients?",
abstract = "Purpose: Psoriasis is one of the most common lifelong lasting dermatologic diseases. According to the latest studies, psoriatic patients have a higher risk of developing cardiovascular diseases. Psoriasis is considered as a systemic inflammatory disease. Several oxidative stress markers have been shown to be elevated in psoriasis. However, a panel of biomarkers has not been used yet. This study was aimed at exploring the connection between a panel of biomarkers (C-reactive protein, asymmetric dimethylarginine, uric acid, total antioxidant capacity, malondialdehyde, and orosomucoid [ORM]) and cardiovascular risk in psoriatic patients. Patients and methods: The inclusion criterion was the onset of psoriasis with skin lesions. Exclusion criteria were impaired renal function (eGFR<60 mL/min/1.73 m2), acute inflammations (urinary, respiratory, skin inflammation, etc), autoimmune disorders (rheumatoid arthritis, systemic lupus erythematosus, or inflammatory bowel disease), and any kind of biological antipsoriatic treatment. Patients with a medical history of myocardial infarction, coronary heart disease, stroke, transient ischemic attack, and carotid artery stenosis were also excluded. Biomarkers were measured by routine procedures, ELISA and HPLC. QRISK{\circledR}2-2017 was used to assess 10-year risk of cardiovascular disease development. Psoriasis severity was measured by the Psoriasis Area and Severity Index. Results: One hundred and fourteen psoriatic patients were enrolled. Only urinary orosomucoid and urinary orosomucoid/urinary creatinine (u-ORM/u-CREAT) ratio showed significant correlation with QRISK score (u-ORM, r=0.245; u-ORM/u-CREAT, r=0.309). When comparing mild psoriatic patients to moderate psoriatic patients, significant differences could only be found in u-ORM and u-ORM/u-CREAT ratio. Conclusion: There seems to be a connection between urinary ORM and cardiovascular risk. U-ORM and u-ORM/u-CREAT ratio could be used as an indicator of low-grade inflammation in mild and moderate psoriasis. However, it is the 10-year follow-up of cardiovascular events that will determine the usefulness of this biomarker panel.",
keywords = "Biomarker, C-reactive protein, Cardiovascular risk, Orosomucoid, Oxidative stress, Psoriasis",
author = "Bal{\'a}zs N{\'e}meth and Iv{\'a}n P{\'e}ter and I. Boncz and Anna Jagicza and Istv{\'a}n Kiss and {\'A}gnes Csergő and T. Kőszegi and P{\'e}ter Kust{\'a}n and I. Horv{\'a}th and Z{\'e}n{\'o} Ajtay",
year = "2019",
month = "1",
day = "1",
doi = "10.2147/TCRM.S197633",
language = "English",
volume = "15",
pages = "831--837",
journal = "Therapeutics and Clinical Risk Management",
issn = "1176-6336",
publisher = "Dove Medical Press Ltd.",

}

TY - JOUR

T1 - Urinary orosomucoid

T2 - A new marker of cardiovascular risk in psoriatic patients?

AU - Németh, Balázs

AU - Péter, Iván

AU - Boncz, I.

AU - Jagicza, Anna

AU - Kiss, István

AU - Csergő, Ágnes

AU - Kőszegi, T.

AU - Kustán, Péter

AU - Horváth, I.

AU - Ajtay, Zénó

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Purpose: Psoriasis is one of the most common lifelong lasting dermatologic diseases. According to the latest studies, psoriatic patients have a higher risk of developing cardiovascular diseases. Psoriasis is considered as a systemic inflammatory disease. Several oxidative stress markers have been shown to be elevated in psoriasis. However, a panel of biomarkers has not been used yet. This study was aimed at exploring the connection between a panel of biomarkers (C-reactive protein, asymmetric dimethylarginine, uric acid, total antioxidant capacity, malondialdehyde, and orosomucoid [ORM]) and cardiovascular risk in psoriatic patients. Patients and methods: The inclusion criterion was the onset of psoriasis with skin lesions. Exclusion criteria were impaired renal function (eGFR<60 mL/min/1.73 m2), acute inflammations (urinary, respiratory, skin inflammation, etc), autoimmune disorders (rheumatoid arthritis, systemic lupus erythematosus, or inflammatory bowel disease), and any kind of biological antipsoriatic treatment. Patients with a medical history of myocardial infarction, coronary heart disease, stroke, transient ischemic attack, and carotid artery stenosis were also excluded. Biomarkers were measured by routine procedures, ELISA and HPLC. QRISK®2-2017 was used to assess 10-year risk of cardiovascular disease development. Psoriasis severity was measured by the Psoriasis Area and Severity Index. Results: One hundred and fourteen psoriatic patients were enrolled. Only urinary orosomucoid and urinary orosomucoid/urinary creatinine (u-ORM/u-CREAT) ratio showed significant correlation with QRISK score (u-ORM, r=0.245; u-ORM/u-CREAT, r=0.309). When comparing mild psoriatic patients to moderate psoriatic patients, significant differences could only be found in u-ORM and u-ORM/u-CREAT ratio. Conclusion: There seems to be a connection between urinary ORM and cardiovascular risk. U-ORM and u-ORM/u-CREAT ratio could be used as an indicator of low-grade inflammation in mild and moderate psoriasis. However, it is the 10-year follow-up of cardiovascular events that will determine the usefulness of this biomarker panel.

AB - Purpose: Psoriasis is one of the most common lifelong lasting dermatologic diseases. According to the latest studies, psoriatic patients have a higher risk of developing cardiovascular diseases. Psoriasis is considered as a systemic inflammatory disease. Several oxidative stress markers have been shown to be elevated in psoriasis. However, a panel of biomarkers has not been used yet. This study was aimed at exploring the connection between a panel of biomarkers (C-reactive protein, asymmetric dimethylarginine, uric acid, total antioxidant capacity, malondialdehyde, and orosomucoid [ORM]) and cardiovascular risk in psoriatic patients. Patients and methods: The inclusion criterion was the onset of psoriasis with skin lesions. Exclusion criteria were impaired renal function (eGFR<60 mL/min/1.73 m2), acute inflammations (urinary, respiratory, skin inflammation, etc), autoimmune disorders (rheumatoid arthritis, systemic lupus erythematosus, or inflammatory bowel disease), and any kind of biological antipsoriatic treatment. Patients with a medical history of myocardial infarction, coronary heart disease, stroke, transient ischemic attack, and carotid artery stenosis were also excluded. Biomarkers were measured by routine procedures, ELISA and HPLC. QRISK®2-2017 was used to assess 10-year risk of cardiovascular disease development. Psoriasis severity was measured by the Psoriasis Area and Severity Index. Results: One hundred and fourteen psoriatic patients were enrolled. Only urinary orosomucoid and urinary orosomucoid/urinary creatinine (u-ORM/u-CREAT) ratio showed significant correlation with QRISK score (u-ORM, r=0.245; u-ORM/u-CREAT, r=0.309). When comparing mild psoriatic patients to moderate psoriatic patients, significant differences could only be found in u-ORM and u-ORM/u-CREAT ratio. Conclusion: There seems to be a connection between urinary ORM and cardiovascular risk. U-ORM and u-ORM/u-CREAT ratio could be used as an indicator of low-grade inflammation in mild and moderate psoriasis. However, it is the 10-year follow-up of cardiovascular events that will determine the usefulness of this biomarker panel.

KW - Biomarker

KW - C-reactive protein

KW - Cardiovascular risk

KW - Orosomucoid

KW - Oxidative stress

KW - Psoriasis

UR - http://www.scopus.com/inward/record.url?scp=85070943796&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85070943796&partnerID=8YFLogxK

U2 - 10.2147/TCRM.S197633

DO - 10.2147/TCRM.S197633

M3 - Article

AN - SCOPUS:85070943796

VL - 15

SP - 831

EP - 837

JO - Therapeutics and Clinical Risk Management

JF - Therapeutics and Clinical Risk Management

SN - 1176-6336

ER -